Neurology and psychiatry coordination
A wide therapeutic area with distinct operational and clinical signatures — we run to the treating clinician's plan, molecule by molecule.
Neurology and psychiatry coordination spans a wide therapeutic area: Parkinson's disease, schizophrenia, Rett syndrome, seizure clusters, acute migraine, primary periodic paralysis, and a growing set of rare neurology orphans. Each carries its own operational and clinical signature.
Neurology and psychiatry therapies we commonly coordinate
- Parkinson's disease — Crexont extended-release carbidopa/levodopa capsules, delivering rapid onset and sustained daytime coverage from a single capsule.
- Schizophrenia — Cobenfy, the first M1/M4 muscarinic agonist approved for schizophrenia in decades — a genuinely new mechanism that does not rely on D2 blockade.
- Rett syndrome — Komzifti (trofinetide), the first FDA-approved therapy for Rett.
- Seizure clusters — Libervant diazepam buccal film for acute intermittent stereotypic seizures.
- Acute migraine — Zavzpret, the first intranasal CGRP receptor antagonist for acute migraine.
- Primary periodic paralysis — Keveyis, the only approved therapy for primary hyperkalaemic and hypokalaemic periodic paralysis.
- Cervical dystonia and chronic sialorrhoea — Myobloc, the only type-B botulinum toxin available, an alternative for patients with reduced response to type-A toxins.
What the treating neurologist or psychiatrist keeps
Dose selection, titration, the monitoring plan, and patient and family conversations remain with the treating clinician. We coordinate sourcing, the dispensing partner's review, and delivery timed to the next scheduled visit so the patient receives the therapy and the clinical plan in the same week wherever possible.